 |
|
|
UpClose
Brent L. Greenwood, A.S.A., M.A.A.A.
Principal, Reden & Anders, Atlanta |
|
|
 Brent
Greenwood, a principal in the Atlanta office of Reden &
Anders, Ltd., is an actuary specializing in financial and
strategic managed care engagements. Brent has extensive experience
with managed care benefit design, pricing, product development,
provider contracting, as well as general financial analysis
In his recently published article "Structuring
a Cost Saving HealthCare Reimbursement Arrangement Product",
he provides an overview of the cost savings potential of the
HRA consumer-driven type product and identifies key benefit
design features and environmental conditions where such a
product could produce cost savings. He also explores how HRA
consumer driven products influence various participants –
employers, employees, insurance entities and providers –
in different ways, and how their point of view needs to be
addressed in the design phase.
Read
More (pdf)
Copyright 2003 by
Reden & Anders. Reprinted with permission.
|
|
 |
|
|
|
LEADING THE WAY by
Charles Crispin, President & CEO, Evergreen RE
 More
often than ever before I hear health care leaders talk
about the escalation in risk. It is not a feeling, obviously,
but a fact that risk is changing quickly and dramatically.
Trend continues to advance virtually across the medical
and pharmaceutical expense spectrum. And it is challenging
all stakeholders in the financing of care. Reinsurers
are pushing much higher limits and retentions, and with
certain reinsurers, increases in the number of exclusions.
On the managed care E&O side of the risk, a near
monopoly situation has developed resulting in very unfavorable
terms to plan sponsors.
These are difficult times for executives
who are trying to minimize unpredictable risk and obtain
reliable and predictable financial results. Not understanding
the impact of coverage limits in a rapidly changing
environment – particularly on the reinsurance side
– can often render coverage useless in certain
cases.
Exclusions for specific incidents
or situations commonly appear benign, but are typically
associated with catastrophic cases. These could include
advanced medical devices, high cost injectables and
other pharmaceuticals, and certain transplant related
expenses – all of which are becoming more and more
sophisticated and costly
Read
More
|
|
 |
|
|
CDH
AND CARVE OUTS